Scarring Alopecia Under Immune Checkpoint Blockade: a Report of Three Cases
DOI:
https://doi.org/10.2340/actadv.v102.2311Keywords:
alopecia, CTLA-4, immune-related adverse event, PD-1Abstract
Abstract is missing (Short communication)
Downloads
References
Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016; 60: 12-25.
https://doi.org/10.1016/j.ejca.2016.02.010 DOI: https://doi.org/10.1016/j.ejca.2016.02.010
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 22372: 320-330.
https://doi.org/10.1056/NEJMoa1412082 DOI: https://doi.org/10.1056/NEJMoa1412082
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532.
https://doi.org/10.1056/NEJMoa1503093 DOI: https://doi.org/10.1056/NEJMoa1503093
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
https://doi.org/10.1056/NEJMoa1200690 DOI: https://doi.org/10.1056/NEJMoa1200690
Lakhmiri M, Cavelier-Balloy B, Lacoste C, Cassius C, Baroudjian B, Delyon J, et al. Nivolumab-induced alopecia areata: a reversible factor of good prognosis? JAAD Case Rep 2018; 4: 761-765.
https://doi.org/10.1016/j.jdcr.2018.05.022 DOI: https://doi.org/10.1016/j.jdcr.2018.05.022
Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJ, et al. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol 2017; 176: 1649-1652.
https://doi.org/10.1111/bjd.15237 DOI: https://doi.org/10.1111/bjd.15237
Cogen AL, Parekh V, Gangadhar T, Lipoff JB. Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma. JAAD Case Rep 2018; 4: 132-134.
https://doi.org/10.1016/j.jdcr.2017.12.002 DOI: https://doi.org/10.1016/j.jdcr.2017.12.002
Bolduc C, Sperling LC, Shapiro J. Primary cicatricial alopecia. J Am Acad Dermatol 2016; 75: 1081-1099.
https://doi.org/10.1016/j.jaad.2014.09.058 DOI: https://doi.org/10.1016/j.jaad.2014.09.058
Ho A, Shapiro J. Medical therapy for frontal fibrosing alopecia: a review and clinical approach. J Am Acad Dermatol 2019; 81: 568-580.
https://doi.org/10.1016/j.jaad.2019.03.079 DOI: https://doi.org/10.1016/j.jaad.2019.03.079
Bertolini M, McElwee K, Gilhar A, Bulfone-Paus S, Paus R. Hair follicle immune privilege and its collapse in alopecia areata. Exp Dermatol 2020; 29: 703-725.
https://doi.org/10.1111/exd.14155 DOI: https://doi.org/10.1111/exd.14155
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Sonja Braasch, Carsten Weishaupt, Eva Spukti, Markus Böhm, Stephan Alexander Braun
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
